{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:54:47Z","timestamp":1773672887857,"version":"3.50.1"},"reference-count":147,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.3816\/cbc.2010.n.009","type":"journal-article","created":{"date-parts":[[2010,2,4]],"date-time":"2010-02-04T23:51:52Z","timestamp":1265327512000},"page":"64-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Visceral Disease in Patients With Metastatic Breast Cancer: Efficacy and Safety of Treatment With Ixabepilone and Other Chemotherapeutic Agents"],"prefix":"10.3816","volume":"10","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2010.n.009_bib1","first-page":"28","article-title":"Tumor-related prognostic factors for breast cancer","volume":"47","author":"Donegan","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CBC.2010.n.009_bib2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.5858\/2000-124-0966-PFIBC","article-title":"Prognostic factors in breast cancer","volume":"124","author":"Fitzgibbons","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.3816\/CBC.2010.n.009_bib3","author":"Breast cancer"},{"key":"10.3816\/CBC.2010.n.009_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1742-1241.2001.tb11161.x","article-title":"Management of advanced breast cancer","volume":"55","author":"Rubens","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.3816\/CBC.2010.n.009_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2004.09.007","article-title":"Liver metastases from breast cancer: management of patients with significant liver dysfunction","volume":"31","author":"Mano","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CBC.2010.n.009_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13651820500471871","article-title":"Surgery for liver metastases from breast cancer","volume":"8","author":"Elias","year":"2006","journal-title":"HPB (Oxford)"},{"key":"10.3816\/CBC.2010.n.009_bib7","series-title":"Breast Cancer Chemosensitivity","first-page":"1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","author":"Gonzalez-Angulo","year":"2007"},{"key":"10.3816\/CBC.2010.n.009_bib8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.309.6967.1501","article-title":"ABC of breast diseases: metastatic breast cancer","volume":"309","author":"Leonard","year":"1994","journal-title":"BMJ"},{"key":"10.3816\/CBC.2010.n.009_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-005-9039-1","article-title":"Prognostic factors for patients with liver metastases from breast cancer","volume":"96","author":"Eichbaum","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1006285726561","article-title":"Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients","volume":"56","author":"Insa","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/A:1010616532332","article-title":"Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer","volume":"66","author":"Alba","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF01975000","article-title":"Human breast cancer: survival from first metastasis. Breast Cancer Study Group","volume":"21","author":"Koenders","year":"1992","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.biopha.2006.07.086","article-title":"Metastatic breast cancer: an updating","volume":"60","author":"Nicolini","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"10.3816\/CBC.2010.n.009_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-005-9117-4","article-title":"Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women","volume":"97","author":"Pentheroudakis","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejso.2006.09.005","article-title":"The significance of the site of recurrence to subsequent breast cancer survival","volume":"33","author":"Imkampe","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib16","series-title":"Diseases of the Breast","first-page":"1205","article-title":"Site-specific therapy of metastatic breast cancer","author":"Ramakrishna","year":"2004"},{"key":"10.3816\/CBC.2010.n.009_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2005.04.008","article-title":"Central nervous metastases in breast cancer patients administered trastuzumab","volume":"31","author":"Duchnowska","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CBC.2010.n.009_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-008-0275-z","article-title":"Risk factors for brain relapse in HER2-positive metastatic breast cancer patients","volume":"117","author":"Duchnowska","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10147-008-0797-8","article-title":"Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer","volume":"14","author":"Ono","year":"2009","journal-title":"Int J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2010.n.009_bib20","first-page":"603s","article-title":"Survival differences in patients with brain metastases according to breast cancer subtypes","volume":"25","author":"Nam","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib21","series-title":"Diseases of the Breast","first-page":"1273","article-title":"Site-specific therapy of metastatic breast cancer","author":"Mentzer","year":"2004"},{"key":"10.3816\/CBC.2010.n.009_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1634\/theoncologist.8-3-241","article-title":"A role for curative surgery in the treatment of selected patients with metastatic breast cancer","volume":"8","author":"Singletary","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.009_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","article-title":"Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis","volume":"59","author":"Solomayer","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.1987.5.5.773","article-title":"Clinical course of breast cancer patients with liver metastases","volume":"5","author":"Zinser","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.009_bib26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2000.18.3.562","article-title":"Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients","volume":"18","author":"Alexandre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib27","first-page":"1696","article-title":"Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites","volume":"5","author":"Twelves","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.4-1-17","article-title":"Monotherapy of metastatic breast cancer: a review of newer agents","volume":"4","author":"Vogel","year":"1999","journal-title":"Oncologist"},{"issue":"suppl 3","key":"10.3816\/CBC.2010.n.009_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/sonc.2003.37268","article-title":"Monotherapy options in the management of metastatic breast cancer","volume":"30","author":"Seidman","year":"2003","journal-title":"Semin Oncol"},{"issue":"suppl 2","key":"10.3816\/CBC.2010.n.009_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience","volume":"9","author":"Crown","year":"2004","journal-title":"Oncologist"},{"issue":"suppl 3","key":"10.3816\/CBC.2010.n.009_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","article-title":"Extending survival with chemotherapy in metastatic breast cancer","volume":"10","author":"O'Shaughnessy","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.009_bib32","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1200\/JCO.1995.13.8.2056","article-title":"Paclitaxel in heavily pretreated breast cancer: a national cancer institute treatment referral center trial","volume":"13","author":"Abrams","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib33","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.1995.13.10.2575","article-title":"Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer","volume":"13","author":"Seidman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib34","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1996.14.6.1858","article-title":"Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer","volume":"14","author":"Nabholtz","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0959-8049(95)00398-3","article-title":"A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines","volume":"32A","author":"Fountzilas","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib36","first-page":"196a","article-title":"Paclitaxel (P) in anthracycline-resistant breast cancer (BC) patients (pts)","volume":"16","author":"Vici","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: and intergroup trial (E1193)","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib38","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342","volume":"22","author":"Winer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib39","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","article-title":"Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer","volume":"16","author":"Seidman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib40","first-page":"65a","article-title":"Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC)","volume":"18","author":"Sola","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib41","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/JCO.2001.19.22.4216","article-title":"Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer","volume":"19","author":"Perez","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib42","first-page":"34a","article-title":"Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC)","volume":"21","author":"Sikov","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib43","first-page":"897","article-title":"Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multi-center cooperative clinical trial","volume":"31","author":"Nishi","year":"2004","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.3816\/CBC.2010.n.009_bib44","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","article-title":"Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer","volume":"83","author":"Holmes","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2010.n.009_bib45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","article-title":"Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response","volume":"13","author":"Seidman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"suppl 8","key":"10.3816\/CBC.2010.n.009_bib46","first-page":"16","article-title":"High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a european cancer center trial","volume":"22","author":"Vermorken","year":"1995","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib47","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","article-title":"Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib48","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.1999.17.10.3038","article-title":"Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer","volume":"17","author":"Gelmon","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib49","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","article-title":"Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a european organization for research and treatment of cancer randomized study with cross-over","volume":"18","author":"Paridaens","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib50","series-title":"Taxol\u00ae (paclitaxel) injection [prescribing information]","year":"2007"},{"key":"10.3816\/CBC.2010.n.009_bib51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1634\/theoncologist.10-9-665","article-title":"Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer","volume":"10","author":"Eniu","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.009_bib52","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","article-title":"Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer","volume":"13","author":"Valero","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib53","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.1996.14.1.58","article-title":"Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer","volume":"14","author":"Hudis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib55","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib56","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib58","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0959-8049(99)00122-7","article-title":"Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian breast group","volume":"35","author":"Sjostrom","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib59","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1008383707159","article-title":"Phase Ii study of docetaxel in patients with liver metastases from breast cancer","volume":"11","author":"Coleman","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib60","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/sj.bjc.6600645","article-title":"Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure","volume":"87","author":"Bonneterre","year":"2002","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib61","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/annonc\/mdh349","article-title":"A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer","volume":"15","author":"Tabernero","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib62","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib63","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial","volume":"19","author":"Hainsworth","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib64","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1023\/A:1012557528952","article-title":"Weekly docetaxol (Taxotere) in patients with metastatic breast cancer","volume":"12","author":"Stemmler","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdf027","article-title":"Phase II study of weekly docetaxel in patients with metastatic breast cancer","volume":"13","author":"Aihara","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib66","series-title":"Taxotere\u00ae (docetaxel) injection concentrate [prescribing information]","year":"2007"},{"key":"10.3816\/CBC.2010.n.009_bib67","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003495-200666070-00007","article-title":"Albumin-bound paclitaxel in metastatic breast cancer","volume":"66","author":"Robinson","year":"2006","journal-title":"Drugs"},{"key":"10.3816\/CBC.2010.n.009_bib68","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1586\/14737140.7.7.919","article-title":"Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy","volume":"7","author":"Henderson","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.3816\/CBC.2010.n.009_bib69","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1200\/JCO.2005.11.013","article-title":"Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer","volume":"23","author":"Ibrahim","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib70","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib71","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3816\/CBC.2007.n.049","article-title":"Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes","volume":"7","author":"Blum","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib72","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib73","series-title":"Abraxane\u00ae for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) [prescribing information]","year":"2005"},{"key":"10.3816\/CBC.2010.n.009_bib74","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/030089169408000407","article-title":"Vinorelbine as single agent in pretreated patients with advanced breast cancer","volume":"80","author":"Barni","year":"1994","journal-title":"Tumori"},{"key":"10.3816\/CBC.2010.n.009_bib76","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.annonc.a058873","article-title":"Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer","volume":"5","author":"Degardin","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib77","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.1994.12.10.2094","article-title":"Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study","volume":"12","author":"Gasparini","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib78","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","article-title":"Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer","volume":"13","author":"Jones","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib79","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.1995.13.11.2722","article-title":"Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer","volume":"13","author":"Weber","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib80","first-page":"146","article-title":"Vinorelbine (NVB) activity in heavily pretreated breast cancer (BC) patients (pts)","volume":"15","author":"Alvarez","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib81","first-page":"125","article-title":"Vinorelbine (VNR) in weekly schedule with G-CSF in patients with advanced breast cancer (ABC)","volume":"15","author":"Ranuzzi","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib82","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.1997.15.4.1395","article-title":"Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer","volume":"15","author":"Livingston","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib83","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1251::AID-CNCR21>3.0.CO;2-F","article-title":"Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma","volume":"86","author":"Ibrahim","year":"1999","journal-title":"Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib84","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q","article-title":"Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma","volume":"92","author":"Zelek","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib85","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","article-title":"Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish breast cancer research group (GEICAM) trial","volume":"8","author":"Martin","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib86","series-title":"Navelbine\u00ae (vinorelbine tartrate) injection [prescribing information]","year":"2005"},{"key":"10.3816\/CBC.2010.n.009_bib87","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1568011023354489","article-title":"The biology and medicinal chemistry of epothilones","volume":"2","author":"Wartmann","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.3816\/CBC.2010.n.009_bib89","first-page":"1429","article-title":"BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-008-0724-8","article-title":"Preclinical discovery of ixabepilone, a highly active antineoplastic agent","volume":"63","author":"Lee","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CBC.2010.n.009_bib91","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1078-0432.CCR-07-2201","article-title":"The epothilones: translating from the laboratory to the clinic","volume":"14","author":"Lee","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib92","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roche","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib93","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2006.10.0784","article-title":"Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes","volume":"25","author":"Denduluri","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib94","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib95","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer","volume":"23","author":"Low","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib96","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"10.3816\/CBC.2010.n.009_bib97","first-page":"ix97","article-title":"Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): data from neoadjuvant and metastatic breast cancer (MBC) trials","volume":"17","author":"Roche","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib98","doi-asserted-by":"crossref","first-page":"225s","DOI":"10.1158\/0008-5472.SABCS-3057","article-title":"Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies","volume":"69","author":"Rugo","year":"2009","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib99","series-title":"Ixempra\u00ae (ixabepilone) for injection [prescribing information]","year":"2007"},{"key":"10.3816\/CBC.2010.n.009_bib100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib101","first-page":"120a","article-title":"Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast carcinoma (MBC)","volume":"19","author":"Wong","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib102","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib103","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouraeil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"Oshaughnessy","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib104","first-page":"60","article-title":"Capecitabine is effective and very well tolerated in Chinese patients with pretreated advanced or relapsed breast carcinoma","volume":"22","author":"Chu","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of capecitabine (Xeloda\u00ae) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib106","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"issue":"14 suppl","key":"10.3816\/CBC.2010.n.009_bib107","first-page":"86s","article-title":"Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC)","volume":"22","author":"Longo","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14 suppl","key":"10.3816\/CBC.2010.n.009_bib108","first-page":"76s","article-title":"Capecitabine monotherapy for elderly patients with metastatic breast cancer (MBC)","volume":"22","author":"Minea","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 5","key":"10.3816\/CBC.2010.n.009_bib109","first-page":"68","article-title":"Capecitabine is active as oral treatment for metastatic breast cancer (MBC), A single institutional experience","volume":"13","author":"Nadal","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/02841860310023165","article-title":"Oral capecitabine in anthracycline- and taxane-pretreated advanced\/metastatic breast cancer","volume":"43","author":"Wist","year":"2004","journal-title":"Acta Oncol"},{"issue":"suppl 3","key":"10.3816\/CBC.2010.n.009_bib111","first-page":"iii40","article-title":"Capecitabine (X) in elderly patients with metastatic breast cancer","volume":"15","author":"Zamora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib112","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.2005.02.167","article-title":"Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women","volume":"23","author":"Bajetta","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib113","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib114","series-title":"Xeloda\u00ae (capecitabine) tablets [prescribing information]","year":"2006"},{"key":"10.3816\/CBC.2010.n.009_bib115","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","article-title":"Advanced breast cancer: a phase II trial with gemcitabine","volume":"13","author":"Carmichael","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00001813-199902000-00003","article-title":"Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer","volume":"10","author":"Possinger","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CBC.2010.n.009_bib117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00001813-199908000-00001","article-title":"Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer","volume":"10","author":"Schmid","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CBC.2010.n.009_bib118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1010679127390","article-title":"Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane","volume":"66","author":"Smorenburg","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib119","first-page":"51b","article-title":"Gemcitabine (G) in pretreated breast cancer","volume":"20","author":"Valerio","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3816\/CBC.2005.n.009","article-title":"A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane","volume":"6","author":"Modi","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib121","series-title":"Gemzar\u00ae (gemcitabine HCl) for injection [prescribing information]","year":"2007"},{"key":"10.3816\/CBC.2010.n.009_bib122","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.2004.12.128","article-title":"Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study","volume":"22","author":"Gradishar","year":"2004","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2010.n.009_bib123","first-page":"7s","article-title":"Epirubicin\/paclitaxel (EP) vs. capecitabine\/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the ASCO breast cancer study group","volume":"24","author":"Lueck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib124","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100449","article-title":"Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK","volume":"71","author":"Gick","year":"2006","journal-title":"Oncology"},{"key":"10.3816\/CBC.2010.n.009_bib125","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2005.05.1383","article-title":"Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer","volume":"24","author":"Blum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib126","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3816\/CBC.2007.n.003","article-title":"Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy","volume":"7","author":"Blum","year":"2007","journal-title":"Clin Breast Cancer"},{"issue":"suppl 1","key":"10.3816\/CBC.2010.n.009_bib127","first-page":"S70","article-title":"Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in and weekly paclitaxel in first-line treatment of metastatic breast cancer (MBC): interim results","volume":"100","author":"Schwartzberg","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib128","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase II trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.3816\/CBC.2010.n.009_bib129","first-page":"24s","article-title":"Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer: (MBC) patients (pts): results of a European phase III study","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2010.n.009_bib130","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0305-7372(05)80004-0","article-title":"Gemcitabine plus docetaxel: a new treatment option for anthracycline-pretreated metastatic breast cancer: patients?","volume":"31","author":"Levy","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"18 suppl","key":"10.3816\/CBC.2010.n.009_bib131","first-page":"582s","article-title":"Capecitabine (X) plus vinorelbine (N) as second-line therapy in Chinese patients (pts) with metastatic breast cancer (MBC)","volume":"24","author":"Xu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"10.3816\/CBC.2010.n.009_bib132","doi-asserted-by":"crossref","first-page":"vii15","DOI":"10.1093\/annonc\/mdl942","article-title":"Oral vinorelbine plus capecitabine (oral vincap) in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)","volume":"17","author":"Lorusso","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib133","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/CBC.2008.n.026","article-title":"Phase I\/II study of ixabepilone plus capecitabine in anthracycline-pretreated\/resistant and taxane-resistant metastatic breast cancer","volume":"8","author":"Bunnell","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib134","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3816\/CBC.2005.n.018","article-title":"Gemcitabine\/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes","volume":"6","author":"Andres","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.3816\/CBC.2010.n.009_bib136","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.009_bib137","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2010.n.009_bib138","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1158\/1078-0432.CCR-08-0974","article-title":"Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer","volume":"14","author":"Dowsett","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib139","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.12-3-253","article-title":"Achievements in systemic therapies in the pregenomic era in metastatic breast cancer","volume":"12","author":"Colozza","year":"2007","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.009_bib140","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib141","unstructured":"Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC \u2192 T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC \u2192 TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Paper presented at: the 2006 San Antonio Breast Cancer Symposium; San Antonio, TX. Abstract 52."},{"issue":"suppl 1","key":"10.3816\/CBC.2010.n.009_bib142","first-page":"S5","article-title":"Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analysis determined by molecular subtypes of disease","volume":"106","author":"Slamon","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2010.n.009_bib143","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1158\/1078-0432.CCR-04-0380","article-title":"Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment","volume":"10","author":"Colleoni","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.009_bib144","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.295.14.1658","article-title":"Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer","volume":"295","author":"Berry","year":"2006","journal-title":"JAMA"},{"key":"10.3816\/CBC.2010.n.009_bib145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00280-008-0806-7","article-title":"Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer","volume":"63","author":"Osako","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15 suppl","key":"10.3816\/CBC.2010.n.009_bib146","first-page":"72s","article-title":"Capecitabine in advanced breast cancer: predictive factors for response","volume":"26","author":"Siva","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CBC.2010.n.009_bib147","first-page":"8s","article-title":"Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB\/CTSU 49907","volume":"26","author":"Muss","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091170009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091170009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:59Z","timestamp":1761512759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091170009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S152682091170009X"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2010.n.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visceral Disease in Patients With Metastatic Breast Cancer: Efficacy and Safety of Treatment With Ixabepilone and Other Chemotherapeutic Agents","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2010.n.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}